High Strength GS-441524 Injection 30mg/ml in 7ml Vial for Cat FIP Treatment via Subcutaneous Injection

GS-441524 is a nucleoside analogue antiviral compound that has been widely referenced in veterinary medicine for the management of feline infectious peritonitis (FIP). As research and treatment experiences have increased over recent years, GS-441524 has become an important compound used in antiviral protocols designed to control viral replication in infected cats.

Feline infectious peritonitis is caused by a mutation of feline coronavirus. Although many cats carry feline coronavirus without severe symptoms, a mutation within the virus can trigger a systemic infection. Once the mutated virus spreads through the body, it may affect organs such as the liver, kidneys, brain, and eyes, leading to serious inflammatory responses.

GS-441524 acts by interfering with the viral RNA replication process. After administration, the compound is converted into an active form that blocks the virus from reproducing inside infected cells. By reducing viral replication, the treatment may help stabilize the condition and allow the cat's immune system to regain control.

This product contains 30mg/ml GS-441524 in a 7ml sterile vial, offering a higher concentration formulation designed to reduce injection volume while maintaining effective dosing levels. The solution is prepared under laboratory production conditions and packaged in sealed vials to maintain product stability during storage and transportation.

The 7ml format provides a practical option for caregivers and veterinary professionals who require a flexible vial size for treatment planning.

Each vial is labeled with production batch information and expiration date to support product traceability and quality management.

FIP is widely regarded as one of the most serious infectious diseases affecting domestic cats. The disease originates from feline coronavirus (FCoV), which is commonly present in cat populations. In most cases, the virus causes only mild intestinal symptoms, but in certain situations it mutates and becomes capable of spreading throughout the body.

Wet FIP is characterized by the accumulation of fluid in the abdomen or chest cavity. Cats may develop abdominal swelling, breathing difficulty, or lethargy as fluid builds up in body cavities.

Dry FIP does not usually involve visible fluid accumulation. Instead, inflammatory lesions may develop in internal organs such as the liver, kidneys, or lymph nodes.

In some cats, FIP may affect the eyes. Symptoms may include iris discoloration, inflammation, or visual impairment.

When the virus spreads to the central nervous system, neurological symptoms such as poor coordination, tremors, or behavioral changes may appear.

Different forms of FIP may require adjusted treatment plans and antiviral dosage levels.

The dosage of GS-441524 is generally calculated based on the cat's body weight and the specific clinical type of FIP. The following values are commonly referenced as dosage guidelines.

Veterinary consultation is recommended to determine the appropriate treatment duration and to monitor the cat's condition during therapy.

• High Concentration Formula - The 30mg/ml concentration allows caregivers to administer smaller injection volumes compared with lower-strength formulations. This can make daily injections easier during extended treatment periods.
• Flexible 7ml Vial Size - The 7ml packaging provides an intermediate option between smaller and larger vial sizes. This flexibility helps caregivers manage treatment supply according to the cat's weight and treatment duration.
• Injectable Administration - The injectable formulation allows the compound to enter the bloodstream directly, ensuring predictable absorption. This method is commonly used in antiviral treatment protocols for FIP.
• Consistent Batch Production - Manufacturing is carried out under controlled laboratory conditions to maintain consistent product concentration and solution stability between batches.
• Room Temperature Storage - Unlike some pharmaceutical products that require strict cold-chain logistics, this GS-441524 formulation can be stored at room temperature, making transportation and storage easier.

• Veterinary Clinics and Animal Hospitals - Veterinary professionals may incorporate GS-441524 injections into treatment protocols for cats diagnosed with FIP. Regular monitoring, including blood tests and physical examinations, is often recommended during treatment.
• Cat Rescue Organizations - Rescue groups frequently encounter kittens or stray cats affected by FIP. Access to antiviral compounds can provide additional options for managing these difficult cases.
• Breeding Facilities - Catteries housing multiple cats may need to respond quickly if infectious diseases appear. Veterinary guidance and antiviral intervention may help manage outbreaks.
• Individual Cat Owners - Many cat owners administer injections at home during FIP treatment cycles under veterinary guidance. A clearly labeled vial and consistent concentration make dosage calculation easier.

To maintain product stability and quality, the following storage guidelines are recommended:

• Store in a cool and dry environment at room temperature
• Avoid direct sunlight or excessive heat exposure
• Keep the vial tightly sealed when not in use
• Use sterile syringes during injection

Under proper storage conditions, the product maintains stability for up to one year from the manufacturing date.

This product is supplied as 30mg/ml GS-441524 injection in a 7ml sterile vial. Protective packaging is used during shipment to reduce the risk of damage during transportation.

Typical supply channels include:

• Veterinary clinics
• Veterinary medicine distributors
• Animal rescue organizations
• Cat care and breeding facilities